



The Nifty previous session ended 0.46% down at 12,690.80. It opened on a flat note and remained extremely volatile throughout the session towards finishing off the day with a Doji candle. A Doji candle near the thick resistance of 12,800-12,840 is pointing towards is a mark of caution. Hence, staying cautious on rise is advised. Base support is now placed around 12,350 levels. Intraday retracement may find buyers around 12,500.

On the Nifty hourly chart; RSI and Stochastic oscillator have started declining from overbought zone, which suggest the benchmark index may again see selling on rise around 12,800 levels. ADX is pointing towards range-bound oscillation with negative bias in the price band of 12,500-12,800. Higher resistance is placed around 12,840 levels.

Nifty patterns on multiple time frames suggest; primary bullish trend suggests; it might get into consolidation in the price band of 12,500-12,800. Higher resistance is placed around 12,840.

Nifty Crucial Supports & Resistances-

Supports- 12500, 12350 Resistances- 12800, 12840

Open Positional Calls-

T+15 Positional Buy-
|Cash Segment| TATA CONSUMER @ 480-475, TGT- 520 & 530, SL- 450

T+7 Positional Buy-
|Cash Segment| CESC @ 580-575, TGT- 605 & 625, SL- 550

T+7 Positional Buy-
|Cash Segment| LUPIN @ 885-880, TGT- 920 & 940, SL- 850

T+7 Positional Buy-
|Cash Segment| JINDAL STEEL @ 216-214, TGT- 230, SL- 206

T+7 Positional Sell-
|Futures Segment| ACC Fut @ 1665-1670, TGT- 1610, SL- above 1700

T+3 Positional Buy-
|Cash Segment| BHARAT FORGE @ 495-494, TGT- 524, SL- 479

Key Contents	Page No.
Result Update	4
Concall Highlights	8
Domestic News	10

Nifty Intraday Chart



Market in Retrospect

The eight-day rally witnessed by India's benchmark indices came to a halt during the weekly options expiry session. Global sentiment remains cautious over deteriorating Covid-19 situation.

The NIFTY index ended at 0.4% lower at 12,693. The broader markets represented by the NIFTY 500 Index ended 0.13% higher, ending at 10343. NIFTY FMCG was the top gainer, gaining by 1.28%, followed by NIFTY Realty which ended by 0.74% higher. NIFTY PSU Bank was the top loser, losing by 2.29%.

Grasim Industries was the top gainer, gaining by 2.97%, followed by HUL and Shree Cement which gained by 2.86% & 2.51% respectively. SBI was the top loser, losing by 3.16%, followed by Coal India and Kotak Bank, which fell by 2.98% & 2.94% respectively.

The Advance: Decline ratio stood at 1121:765

Market Turnover (In Crore) 12-11-2020

Name	Last	Previous
NSE Cash	63576.57	81743.31
NSE F&O	5531324.77	3638198.82
BSE Cash	3,108.03	4,287.20
BSE F&O	*NA	331.45

FII Derivatives Flow (In Crore) 11-11-2020*

Instrument	Purchase	Sale	Net
Index Future	5745.46	5506.92	238.54
Index Option	486614.21	486731.98	117.77
Stock Future	20477.85	20870.00	392.15
Stock Option	9536.51	9515.40	21.11

Institutional Flow (In Crore) 11-11-2020*

Institution	Purchase	Sale	Net
FII	14549.31	8342.12	6207.19
DII	4578.17	8042.03	3463.86

*Data not updated till 6PM

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Grasim Industries	2.97	2.80	3830555	2415099
HUL	2.86	4.27	3010512	2327540
Shree Cement	2.51	5.41	178595	80693
Hindalco Industries	2.23	11.34	40805593	23789780
ITC	1.46	7.58	46367792	43462840

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
NTPC	2.26	4.61	33374610	45080090
Indusind Bank	2.38	7.67	28387177	38545120
Kotak Bank	2.94	4.73	6775199	7156108
Coal India	2.98	1.88	35738360	16266080
SBI	3.16	3.73	58859905	102783900

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	43357.19	236.48	0.54	4.88	6.81	13.00	7.47
Nifty	12690.80	58.35	0.46	4.71	6.37	12.22	6.52
BSE M Cap	15740.86	77.73	0.50	2.55	7.11	9.66	6.54
BSE S Cap	15466.31	183.09	1.20	2.18	3.75	11.80	14.59
Nifty MC 100	18182.90	107.90	0.60	2.86	6.99	11.77	8.15
BSE Auto	18702.58	87.38	0.47	3.57	2.18	6.27	2.26
BSE Capgoods	15863.86	208.11	1.33	7.25	15.56	18.67	13.28
BSE FMCG	11536.19	158.04	1.39	3.28	3.81	1.80	4.08
BSE Metal	9242.78	22.32	0.24	6.55	16.66	7.71	5.07
BSE Oil&Gas	12876.68	39.01	0.30	5.04	6.99	3.46	15.92
BSE Healthcare	19571.63	87.26	0.45	1.03	4.04	2.49	49.10
BSE Power	1856.12	6.58	0.36	5.11	14.43	17.82	5.22
BSE Realty	1884.08	15.53	0.83	6.48	11.96	15.77	13.22
BSE ConsDur	25474.80	21.49	0.08	1.48	4.06	17.30	2.06
BSE Bank	32435.00	679.55	2.05	7.45	20.83	28.64	8.01
BSE IT	21579.63	57.62	0.27	0.11	3.38	18.29	42.60

Bond Markets							
Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	0.94	0.03	3.22	23.73	22.00	39.90	51.21
UK	0.41	0.01	1.94	73.08	49.45	70.89	49.75
Brazil	3.35	0.01	0.42	7.23	5.15	1.90	14.06
Japan	0.03	0.01	26.83	36.36	6.25	33.33	250.00
Australia	0.91	0.08	8.14	23.35	8.04	0.44	28.76
India	5.91	0.00	0.05	0.56	0.12	0.94	10.08
Switzerland	0.44	0.01	3.02	14.94	10.30	1.33	13.85
Germany	0.51	0.01	1.18	19.47	5.87	14.77	103.57

Currency							
Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	74.65	0.27	0.37	0.35	1.84	0.24	4.26
USD Index	92.85	0.20	0.21	0.35	0.23	0.64	5.55
YUAN	6.62	0.01	0.18	0.19	1.91	4.80	5.87
GBP	1.32	0.00	0.18	0.38	1.03	1.26	2.75
EUR	1.18	0.00	0.32	0.09	0.02	0.26	7.32
YEN	105.33	0.10	0.09	1.75	0.00	1.50	3.49

Freight							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1141.00	59.00	4.92	6.78	36.86	25.91	15.73
Baltic Dirty	407.00	2.00	0.49	0.49	0.73	18.60	56.75
SG Dubai HY	1.03	0.16	13.45	106.00	56.06	930.00	12.71

Global Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	29397.63	23.29	0.08	5.57	1.94	5.08	6.16
Nasdaq	11786.43	232.57	2.01	1.69	0.76	7.03	38.89
S&P 500	3572.66	27.13	0.77	3.75	1.09	5.69	15.55
FTSE100	6363.08	18.17	0.28	7.75	6.04	1.33	13.60
CAC40	5409.54	33.98	0.62	8.57	8.67	6.66	8.59
DAX	13146.38	65.70	0.50	4.63	0.09	0.70	1.00
Mexico IPC	40858.95	454.37	1.12	9.03	6.56	5.76	5.20
Brazil Bovespa	104808.8	258.20	0.25	7.09	7.51	2.64	1.82
Russian RTS	1236.37	2.60	0.21	5.61	6.32	5.41	14.69
Japan Nikkei	25520.88	171.28	0.68	5.87	8.33	11.72	8.51
Hang Seng	26169.38	57.60	0.22	1.84	6.17	3.67	3.31
Taiwan Index	13221.78	40.41	0.30	2.35	2.05	4.35	14.77
Shanghai Comp	3338.68	3.52	0.11	0.56	0.59	0.58	14.54
KOSPI	2475.62	10.25	0.41	2.56	2.99	1.78	15.63
Malaysia KLCI	1590.78	20.70	1.32	5.95	4.76	2.19	1.18
Jakarta Comp	5458.60	50.91	0.92	3.77	7.18	4.30	11.69
Philippine SE	7024.26	11.22	0.16	8.67	18.31	17.17	12.33
Thai Exch	1336.31	9.03	0.67	5.69	4.94	0.04	17.83

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	41.52	0.10	0.24	7.12	5.38	2.62	26.85
BRENT Crude	43.85	0.08	0.18	7.21	3.98	5.92	24.53
Natural Gas	3.01	0.02	0.66	2.35	7.95	0.47	11.73

LME							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1869.67	3.62	0.19	4.12	2.78	2.43	28.36
Silver(\$/Ounce)	24.29	0.00	0.02	4.30	3.27	4.82	44.80
Aluminium	1898.25	10.45	0.55	0.20	3.86	8.45	6.55
Copper	6866.00	47.25	0.68	0.55	1.46	7.59	17.18
Zinc	2608.00	21.25	0.81	0.97	7.81	8.94	2.60
Lead	1855.50	24.25	1.32	1.45	3.17	4.45	11.28

Agro Commodities							
Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	112.50	0.55	0.49	3.73	0.90	3.43	6.29
Cotton	71.29	0.09	0.13	0.11	3.05	12.91	3.12
Sugar	14.79	0.30	2.07	2.14	6.86	10.37	8.75
Wheat	602.75	3.25	0.54	1.75	0.84	18.83	8.31
Soybean	1151.50	1.00	0.09	4.33	11.07	29.71	19.82

Power Corporation of India Ltd

Power Grid Corporation of India posted 20.34 per cent year-on-year growth in consolidated net profit at INR3,094.10 crore for the quarter ended September 30. It had posted a profit of INR2,571.10 crore for the corresponding quarter last year. Revenue from operations grew 6.16 per cent YoY to INR9,831 crore. Total expenditure of the company declined to INR5,986.37 crore in Q2FY21 over INR6,303.31 crore in Q2FY20.

Aurobindo Pharma

Aurobindo Pharma Ltd reported a 26% increase in consolidated net profit at INR805.65 crore in the second quarter ended September. The company had posted a consolidated net profit of INR639.53 crore in the same quarter last fiscal. Consolidated total revenue from operations during the period under review stood at INR6,483.44 crore as against INR5,600.47 crore in the corresponding quarter last fiscal. During the second quarter, the US formulation revenue stood at INR3,189.8 crore as against INR2,835.5 crore in same period last fiscal, a growth of 12.5%, while Europe formulation revenue was at INR1,514.8 crore, a growth of 8.1% from the year-ago quarter. The company said it received final approval for 10 ANDAs from USFDA.

Finolex Cables

Finolex cables, one of India's major manufacturer of electrical and communication cables, reported 10.7% lower Sep-20 quarter top line sales revenues at INR639.41cr. Finolex services the electrical cables segment predominantly and their business demand is largely industrial in nature. That explains the sharp fall in top line and bottom line in Jun-20 quarter. For the Sep-20 quarter, the operating profits were down 6.46% at INR81.57cr. However, the operating margin or OPM was marginally higher moving from 12.18% in the Sep-19 quarter to 12.76% in the Sep-20 quarter on the back of a lower sales base. Profit after tax (PAT) for the Sep-20 quarter was down 19.28% at INR102.39cr. This resulted in PAT margins contracting from 17.72% to 16.01% in Q2 on a yoy basis. Electrical cables are the principal product of Finolex Cables. It accounts for 67% of the revenues of Finolex Cables but a whopping 95% of the EBIT profits of the company.

Godrej Industries

Godrej Industries reported 9.22% lower Sep-20 quarter top line sales revenues at INR2,386.29cr. Godrej being a largely diversified company spread across daily, food and chemicals did manage to hold its top line even in the midst of the COVID pandemic in Jun-20 quarter. It did show a sharp bounce from the June levels, but yet to recoup pre-COVID level. For the Sep-20 quarter, the operating profits were down 22.098% at INR72.92cr. This resulted in the operating margin or OPM dropping from 3.56% in the Sep-19 quarter to 3.06% in the Sep-20 quarter. However, Profit after tax (PAT) for the Sep-20 quarter was up by just 19.59% at INR204.06cr. This only refers to the continuing operation and the exceptional gain on discontinued operations of Godrej Nature's basket in Sep-19 quarter is not considered. This resulted in PAT margins expanding marginally from 16.91% to 17.13% in Q2. In the Sep-19 quarter, Godrej Industries logged a one-time gain of INR201cr from the sale of its holding in Godrej Nature's Basket to Spencer Retail.

Bharat Forge

Bharat Forge reported a consolidated net loss of INR1.32 crore in the second quarter ended September 30 hit by the coronavirus pandemic induced disruptions. The company had posted a consolidated net profit of INR205.49 crore in the same quarter last fiscal. Consolidated revenue from operations during the period under review stood at INR1,376.09 crore as against INR2,155.20 crore in the year-ago period.

GIC Housing

GIC Housing Finance reported a net profit of INR20.60 crore in the second quarter ended September of this fiscal. It had posted a net loss of INR9.97 crore in the same quarter a year ago. The company had registered a net loss of INR55.71 crore in the first quarter ended June 2020 of this fiscal. Total income rose marginally to INR316.02 crore in July-September quarter of 2020-21 from INR313.24 crore in the same period a year ago. The company has obtained physical possession of properties under SARFAESI Act and is in the process of selling the same. These properties are classified as 'Assets Held for Sale' and carried at the lower of cost or realizable value.

GMDC

Gujarat Mineral Development Corp (GMDC) posted 67.1 per cent decline in consolidated profit after tax at INR40.5 crore for the quarter ended March 31, 2020. The company posted a profit after tax of INR123.4 crore in the year-ago period. The income during January-March 2020 declined to INR467.7 crore, from INR570.5 crore in the year-ago period. The company said its board has recommended a dividend of INR2 per equity share of INR2 each for 2019-20.

National Aluminium Company Ltd

National Aluminium Company Ltd reported a consolidated profit of INR107.27 crore for the quarter ended September 30. The company had posted a loss of INR28.25 crore for the year-ago period. The company's income during July-September period declined to INR2,399.05 crore from INR2,420.11 crore in the year-ago period. The total alumina sales during the second quarter was 285,718 MT. During the first half of the ongoing fiscal, the company achieved 3-fold jump with export of 9,3730 MT aluminium compared to 3,0561 MT in the corresponding period last year. During the quarter registering sales of 58,574 metric tonne (MT) of aluminium compared to 16,305 MT in corresponding period last year.

NBCC

NBCC reported a consolidated net profit of INR45.61 crore for the quarter ended September. The company had posted a net loss of INR90.91 crore in the year-ago period. Total income stood at INR1,426.27 crore in the second quarter of this fiscal year as against INR1,720.46 crore in the corresponding period of the previous year.

Petronet LNG

Net profit of Petronet LNG declined 15.94% to INR927.30 crore in the quarter ended September 2020 as against INR1103.14 crore during the previous quarter ended September 2019. Sales declined 33.39% to INR6235.78 crore in the quarter ended September 2020 as against INR9361.18 crore during the previous quarter ended September 2019.

Page Industries

Page Industries reported 4.53% lower Sep-20 quarter top line sales revenues at INR740.31cr. Being in the garments business, the company top line got badly impacted by the lockdown and social distancing norms put by the government. For the Sep-20 quarter, the operating profits were up 11.41% at INR149.7cr. The operating profit was generated on the back of lower raw material costs and reduction in miscellaneous expenses. This resulted in the operating margin or OPM expanding significantly from 17.33% in the Sep-19 quarter to 20.22% in Sep-20 quarter. Profit after tax (PAT) for the Sep-20 quarter was, however, down by 3.18% at INR110.87cr. The tax payout at INR35cr in the Sep-20 quarter was twice the tax paid in the Sep-19 quarter. However, due to the lower sales base, the PAT margins still expanded marginally from 14.77% to 14.98% in Q2.

Natco Pharma

Net profit of Natco Pharma declined 41.98% to INR70.90 crore in the quarter ended September 2020 as against INR122.20 crore during the previous quarter ended September 2019. Sales rose 4.63% to INR478.90 crore in the quarter ended September 2020 as against INR457.70 crore during the previous quarter ended September 2019.

LIC Housing

LIC Housing Finance reported about 3 per cent rise in net profit at INR789.67 crore for September quarter of this fiscal year. The housing financier had posted a net profit of INR767.95 crore in the same quarter a year ago. In June quarter, the profit was INR824.08 crore. Total income grew marginally to INR4,987.64 crore in July-September 2020-21 as against INR4,980.80 crore in the year-ago period.

Shree Cement Ltd

- In Q2FY21, the company reported a 7.9% YoY increase in sales to INR30,223 mn. Cement & clinker volumes increased by 14.2% YoY to 6.5 MMT.
- Realization contracted by 5.5% YoY to INR4,627/ton (-1.9% QoQ), driven by seasonal weakness of cement prices.
- Per ton cost fell to INR3,114/ton (-9% YoY; -5.5% QoQ), driven by lower power and fuel cost (-30.4% YoY; - 6.3% QoQ). Cost decline was further led by a reduction in fixed costs, which lowered other expenses to INR732/ton (-5.6% YoY; +3.8% QoQ) & Employee expenses to INR265/ton (-18% YoY; - 24.5% QoQ)
- EBITDA/ton came in at INR1,513/ton versus INR1,421/ton in Q1FY21 (QoQ) and INR1,475/ton (YoY). EBITDA increased by 17% YoY to INR9,880 mn while EBITDA margin increased by 256 bps YoY to 32.7% in Q2FY20.
- In H1FY21, Company has repaid long term debt INR5,650 mn.
- Q2FY21 PAT increased by 77.1% YoY to INR5,472 mn.

Apollo Hospitals Enterprise Ltd

- Consolidated Revenue from operations declined by 2.8% YoY to INR2761 cr.
- Consolidated EBITDA declined by 27.5% YoY to INR300 cr.
- Consolidated EBITDA margin was 10.9% in Q2FY21 (-370 bps YoY).
- Healthcare segment revenue declined by 17% YoY to INR1242.7 cr on a consolidated basis.
- Pharmacy segment revenue increased by 15% YoY to INR1351.88 cr.
- AHLL revenue declined by 5.5% YoY to INR171.52 cr.
- Healthcare segment reported an EBIT of INR64.04 cr in Q2FY21 as against an EBIT of INR193.54 cr in Q2FY20 (-67%YoY). EBIT margin for Q2FY21 was 5.2% as against 13% in Q2FY20.
- Pharmacy segment reported an EBIT of INR86.87 cr in Q2FY21 (+22.6% YoY). EBIT margin for Q2FY21 was 6.4% as against 6% in Q2FY20.
- AHLL reported an EBIT of INR0.13 cr in Q1FY21 as against an EBIT of INR(3.81) cr in Q2FY20.
- Net Profit for Q2FY21 was INR60 cr as against a Net Profit of INR86 cr in Q2FY20.
- Of the 8,816 owned hospital beds capacity, 7,364 beds were operational and had an occupancy of 56% in Q2 FY21.
- Q2FY21 occupancy across the group was at 4,119 beds (56% occupancy) as compared to 2,742 beds (38% occupancy) in Q1FY21. The Q2FY21 occupancy in mature hospitals was at 2,846 beds (54% occupancy). New hospitals had an occupancy of 1,273 beds (61% occupancy) in Q2FY21.
- Inpatient Volumes across the group increased by 30% QoQ from 63,105 to 82,153.
- ARPOB registered a growth of 4.9% in Q2FY21 as compared to the previous year.
- The total number of pharmacies as on Sep 30, 2020 was 3,850. Gross additions of 92 stores with 22 stores closed; Net addition of 70 stores in Q2 FY21 & 84 stores in H1FY21.
- Apollo Hospitals Enterprise Ltd (AHEL) will acquire 50% balance stake in Apollo Gleneagles Hospital, Kolkata from the IHH Group to make it a wholly owned subsidiary of AHEL at a cash consideration of INR410 cr.
- The Board of Directors have approved the proposal to raise funds by way of issue of securities through preferential allotment and / or Qualified Institutional Placement (QIP) or any equivalent capital raising method permitted by applicable laws, subject to approval of the shareholders, up to a maximum aggregate limit of INR1500 cr.
- The Scheme of Arrangement ('the Scheme') for transfer of front-end retail pharmacy business included in the standalone pharmacy segment ('divestment business') to Apollo Pharmacies Limited ('APL' or 'Transferee Company'), a wholly owned subsidiary of Apollo Medicals Private Limited ('AMPL') for an overall cash consideration of Rs.527.8 cr was approved by the National Company Law Tribunal vide their Order dated August 3, 2020. Pursuant to the Scheme becoming effective, the Company invested Rs.36.5 cr and its ownership interest in AMPL changed to 25.50%, resulting in loss of control with effect from September 1, 2020. Net gain associated with the loss of control of INR35.44 cr has been included under Exceptional items.
- AHEL will increase stake in Apollo Medics, Lucknow to 51% to make it a subsidiary of AHEL for a cash consideration of INR3.98 cr.

Apollo Hospitals Enterprise Ltd

- Latter half of Q2FY21 saw visible traction in both Covid and non Covid patients across hospitals.
- **October saw an overall occupancy of 65%; occupancy is gaining further momentum in November. There was a 20% increase in both revenue and occupancy in October compared to Q2FY21 average.**
- **Covid revenue was 26% of Hospitals revenue. Covid's share of occupied beds was 36%. Covid ARPOB was 20% lower than overall ARPOB.**
- Covid tests only contributed to around 7% of overall AHLL revenue for H1FY21. In terms of total diagnostics revenue, Covid tests contributed 30%.
- Apollo has treated a total of 23000 Covid patients till date and about 2.5 lakhs Covid tests have been carried out till date.
- Revenue from diagnostics has a scope to increase to Rs 500 cr in three years from Rs 150 cr currently.
- **Post pharmacy restructuring, 80% of Pharmacy EBITDA will flow in to Apollo Hospitals (AHEL).**
- **Post restructuring of pharmacy business, minimal capex will be carried out at the back-end, i.e., for Apollo Hospitals.**
- The Apollo 24x7 app is doing phenomenally well. In just over 6 months, 5 million users have been registered on the app. The app will enable users to get more and more home based services.
- According to Times Health Survey for 2020, four Apollo hospitals have featured on the list of top ten multispecialty hospitals in India.
- Apollo hospitals on an overall basis have been credited for carrying out the highest number of robotic surgeries in India.
- **While the usage of funds post the capital raise of a maximum amount of Rs 1500 cr has not been crystallised as yet, broadly the funds would be used for investment in Apollo Gleneagles, Kolkata to the tune of Rs 410 cr, investment in 24x7 app, reduction of debt and bolt on acquisitions.**
- EBITDA Margins (Pre Ind AS 116) in Q2FY21 for hospitals were low compared to usual pre Covid EBITDA margins as there was a drop in outpatients revenue as well as drop in outstation patients, who travel from far/nearby places to get themselves treated in an Apollo hospital.
- **While outstation patients have reduced drastically in the flagship hospitals of Apollo, the proportion of local patients has increased. This is a positive development and these patients are expected to stick on with the respective hospitals. The current proportion of local patients stands at 60% compared to 30% seen during pre Covid times.**

- **The organic capex for next two-three years would be low, however, bolt on acquisition opportunities would be considered. The bolt-on opportunities would be 200-300 beds hospitals in large towns/cities and up to 200 beds in small towns. The reduction in ALOS along with increasing use of technology in surgical and robotic procedures would make no practical sense in taking over hospitals with bed capacities over 300.**
- **The ARPOB has increased significantly for the AP/Telangana region to Rs 45017 from Rs 34288 because high end surgical works were done in these regions and severe cases of Covid were also tackled.**
- **The flow of international patients is nowhere close to normal. Some patients are coming from Bangladesh and Myanmar. Normalcy in the flow of international patients is expected in Q4FY21.**
- **Proton facility has also suffered because of dearth in international patients. Once foreign patients come back there would be pick up in occupancy.**
- **About Rs 180 cr of cost savings has been achieved in H1FY21. This includes cost of consummables, rationalisation of salary and doctors' guarantee money, reduced outsourcing costs and reduced marketing and travel expenses. Structural cost saving of 12-15% is attempted for the long run.**

GDP to contract 8.6% in Q2; India has entered recession for first time: RBI official

- The gross domestic product (GDP) is likely to contract by 8.6 per cent for the July-September period, which means India will enter into a recession for the first time in history in the first half of this fiscal with two successive quarters of negative growth due to the Covid-19 pandemic, as per an RBI official.
- Researchers have used the 'nowcasting' method to arrive at the estimates ahead of the official release of data and their views in an article in RBI's monthly bulletin released on Wednesday do not constitute the central bank's views.

DHL Express to invest about Rs 6,600 crore in Asia Pacific region

DHL Express will invest EUR 750 million about Rs 6,600 crore in the Asia Pacific region on the back of e-commerce growth. DHL Express will invest EUR 690 million between 2020 and 2022 to build or expand its facilities in key growth markets of Australia, Japan, Hong Kong SAR and South Korea. DHL Express currently has 23 dedicated aircraft in its Asia Pacific fleet, and operates approximately 1,040 flights per day. The growth in e-commerce shipment volumes will continue to outpace the available air cargo capacity in the industry, strengthening the case to invest in adding new dedicated aircraft to our fleet, open up new routes, and supplement our fleet with charter flights. Equally, it intends to spend close to EUR 60 million to bolster its Asia Pacific air network such as introducing direct, new and frequent flight routes.

Lupin, Concord Biotech get USFDA nod for generic immunosuppressant capsules

Lupin said that in alliance with Concord Biotech, it has received approval from the US health regulator to market generic immunosuppressant Tacrolimus capsules used in the American market. In alliance with Concord Biotech, the company has received approval from the United States Food and Drug Administration (USFDA) to market Tacrolimus capsules USP, in the strengths of 0.5 mg, 1 mg, and 5 mg. The product is a generic version of Astellas Pharma US, Inc's Prograf capsules in the same strengths.

India's Petronet has no plans to invest in LNG developers

Petronet LNG Ltd has no plans to invest in liquefied natural gas (LNG) developers as the market is awash with cheaper fuel, its finance chief said, indicating it may shelve plans to invest in Tellurian Inc's U.S. project. Petronet, the country's top gas importer, has time until December-end to consider investing \$2.5 billion for 5 million tonnes per annum (mtpa) of LNG in Tellurian's Driftwood project to end-2020. Petronet has a deal to purchase 7.5 mtpa of LNG from Qatar and 1.44 mtpa from Exxon Mobil Corp's Gorgon project in Australia.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Procter & Gamble Hygiene & Health Care Ltd	Cash dividend of INR105 effective 13-11-2020
Prince Pipes & Fittings Ltd	Cash dividend of INR1.50 effective 13-11-2020
Kohinoor Foods Ltd	Corporate meeting effective 13-11-2020
Indiabulls Integrated Services Ltd	Corporate meeting effective 13-11-2020
Globe International Carriers Ltd	Corporate meeting effective 13-11-2020

Domestic Events

- **Upcoming Result:** 3M India, Ahluwalia Contracts, Apex Frozen Foods, Borosil, Dhampure Speciality Sugars, Future Enterprises, Future Retail, General Insurance Corporation Of India, Graphite India, Hindustan Aeronautics, Kennametal India, Manpasand Beverages, MEP Infrastructure Developers, Sreeleathers
- India WPI Inflation for October 2020.
- India Foreign Exchange Reserve for November 06, 2020.

Global Events

- Euro Area GDP for Q3 2020.
- Euro Area Balance of Trade for September 2020.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

Sudipto Datta, Compliance Officer

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: compliance@smifs.com

Website: www.smifs.com